Seres Posts $16.3M Q3 Loss, Cash Lasts Only Through Q1 2027
MCRB is trading near its 52-week low of $1.675 (3.6% above the low).
Summary
Seres burned through the quarter and ended September 30 with $17.5 million in cash after posting a $16.3 million third-quarter loss, a net loss that widened on an impairment charge, with third-quarter revenue of $593,000 and an EPS of -1.63. Management says that cash, plus a $12.5 million Nestlé payment received in October, funds operations only through Q1 2027 — a runway that leaves little room for error at a company trading near its 52-week low. The next hard deadline is the planned Q1 2027 submission of the SER-155 irEC study design to the FDA; the program rests on a small investigator-sponsored trial where 12 of 15 participants responded at Day 15, not on new company-run data. This follows the 8-K disclosing CFO Marella Thorell's resignation effective November 15, 2026, leaving the finance function in transition just as the company needs to raise capital. The going concern warning persists, and the runway projection excludes any future partnerships or other financing.
At the time of this announcement, MCRB was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $1.68 to $29.98. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.